Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) Research Peptide

GLP1 – T is a 39-amino-acid dual receptor agonist peptide that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, studied for its role in dual incretin pathway signaling and metabolic regulation in research models. Supplied as a lyophilized vial for in-vitro laboratory research use only. Research-grade specs Sequence length: 39 amino acids Class: Dual GIP / GLP-1 agonist Half-life: ~5 days Studied applications Comparative GLP-1 vs dual-agonist research Glucose and lipid metabolism studies Body-composition research (SURMOUNT trial framework) Receptor-binding affinity comparison studies Quality & trust ≥99% HPLC purity, third-party tested Mass spectrometry identity confirmation LAL endotoxin testing on every batch Batch-specific Certificate of Analysis included USA same-day shipping (orders before 2pm CT M-F) Related research: GLP- (S) · GLP – (R) Research literature GLP-T has been the subject of 1,927 peer-reviewed publications indexed in PubMed. Selected recent literature for research reference: Johansson E et al. (2026). Cost-effectiveness of GLP-T versus GLP-S for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial. J Med Econ. PMID: 42012820 Kanumilli N et al. (2026). Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of GLP-T versus GLP-S semaglutide 1 mg in patients with type 2 diabetes in the UK. J Med Econ. PMID: 41771166 Soliman A et al. (2026). GLP-T as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. J Diabetes Metab Disord. PMID: 41883513 Alexander L et al. (2026). Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach. Obes Pillars. PMID: 41859682 Mondoh A et al. (2026). Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions. Obes Pillars. PMID: 41815755 References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.